Európska únia - slovenčina - EMA (European Medicines Agency)

co.don gmbh - sféroidy chondrocytov spojených s ľudskou autológnou matricou - ochorenia chrupavky - iné lieky na poruchy muskuloskeletálneho systému - oprava symptomatická kĺbovej chrupavky vady kondylu femuru a pately kolena (medzinárodná chrupavky oprava spoločnosť [icrs] triedy iii alebo iv) s vadou veľkosti do 10 cm2 u dospelých.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medochemie ltd., cyprus - venlafaxín - 30 - antidepressiva

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medochemie ltd., cyprus - venlafaxín - 30 - antidepressiva

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

egis pharmaceuticals plc, maďarsko - venlafaxín - 30 - antidepressiva

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

egis pharmaceuticals plc, maďarsko - venlafaxín - 30 - antidepressiva

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

egis pharmaceuticals plc, maďarsko - venlafaxín - 30 - antidepressiva

Európska únia - slovenčina - EMA (European Medicines Agency)

astrazeneca ab - benralizumab - astma - drogy obštrukčnej choroby dýchacích ciest, - fasenra je označené ako pridať na udržiavaciu liečbu dospelých pacientov s ťažkou eozinofilná astma nedostatočne kontrolované napriek vysokými dávkami inhalačných kortikosteroidov, plus dlhodobo pôsobiaceho β-agonistov.

Európska únia - slovenčina - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - liečivá na dermatitídu okrem kortikosteroidov - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

opella healthcare slovakia s.r.o., slovensko - nesteroidové antiflogistiká na lokálne použitie - 29 - antirheumatica, antiphlogistica, antiuratica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

angelini pharma Österreich gmbh, rakúsko - nesteroidové antiflogistiká na lokálne použitie - 29 - antirheumatica, antiphlogistica, antiuratica